Drug Trial Radar · NCT04155918
Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients
Last checked: Nov 19, 2026Latest source record: Nov 19, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Feb 3, 2020
Primary completion
Sep 3, 2020
Study completion Sep 3, 2020
Sponsor
- Lead sponsor
- Arthrosi TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Nov 7, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is designed to evaluate the PK/PD, safety and tolerability of AR882 alone or in combination with febuxostat or allopurinol when administered to gout patients.
Conditions
- Gout Patients
Interventions
Group 1: AR882 Alone and in Combination with Febuxostat (FBX)Drug
AR882 + Febuxostat, AR882 alone, Febuxostat alone
Group 2: AR882 Alone and in Combination with Allopurinol (ALLO)Drug
AR882 + Allopurinol, AR882 alone, Allopurinol alone
Primary outcomes
What the sponsor says the trial is designed to measure.
- PD profile of AR882 administered alone or in combination with febuxostatTime frame: 22 Days
- PD profile of AR882 administered alone or in combination with allopurinolTime frame: 22 Days
- Serum uric acid (sUA) response rateTime frame: 22 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Christchurch Clinical Studies Trust, Ltd (CCST)
Christchurch, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.